| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Damian M Herz, Brian N Haagensen, Mark S Christensen, Kristoffer H Madsen, James B Rowe, Annemette Løkkegaard, Hartwig R Siebne. The acute brain response to levodopa heralds dyskinesias in Parkinson disease. Annals of neurology. vol 75. issue 6. 2014-08-25. PMID:24889498. |
in parkinson disease (pd), long-term treatment with the dopamine precursor levodopa gradually induces involuntary "dyskinesia" movements. |
2014-08-25 |
2023-08-13 |
Not clear |
| Patrick Oeckl, Bastian Hengerer, Boris Ferge. G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. Experimental neurology. vol 257. 2014-08-13. PMID:24747358. |
g-protein coupled receptor 6 deficiency alters striatal dopamine and camp concentrations and reduces dyskinesia in a mouse model of parkinson's disease. |
2014-08-13 |
2023-08-13 |
mouse |
| Clare J Finlay, Susan Duty, Anthony C Verno. Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies. Frontiers in neurology. vol 5. 2014-06-27. PMID:24971074. |
dopamine replacement therapy in the form of levodopa results in a significant proportion of patients with parkinson's disease developing debilitating dyskinesia. |
2014-06-27 |
2023-08-13 |
human |
| David Lindenbach, Kristin B Dupre, Karen L Eskow Jaunarajs, Corinne Y Ostock, Adam A Goldenberg, Christopher Bisho. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease. Brain research. vol 1537. 2014-06-25. PMID:24060645. |
our results support previous work that the striatal perk pathway is dysregulated after dopamine depletion, but call into question the utility of perk as a biomarker of dyskinesia expression. |
2014-06-25 |
2023-08-12 |
rat |
| Alice Manson, Paola Stirpe, Anette Schra. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. Journal of Parkinson's disease. vol 2. issue 3. 2014-06-20. PMID:23938226. |
the important aetiological role of non-physiological pulsatile stimulation of dopaminergic receptors is increasingly recognized and more continuous dopaminergic stimulation with the longer acting dopamine agonists has been shown to reduce and delay the onset of dyskinesias. |
2014-06-20 |
2023-08-12 |
Not clear |
| Karen L Eskow Jaunarajs, David G Standaert, Tacey X Viegas, Michael D Bentley, Zhihao Fang, Bekir Dizman, Kunsang Yoon, Rebecca Weimer, Paula Ravenscroft, Tom H Johnston, Michael P Hill, Jonathan M Brotchie, Randall W Moreadit. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 12. 2014-06-20. PMID:24014074. |
currently available dopaminergic drugs such as levodopa and dopamine (da) receptor agonists impart considerable improvement in parkinson's disease (pd) motor symptoms but often lead to significant motor complications including "wearing-off" and dyskinesia. |
2014-06-20 |
2023-08-12 |
rat |
| Jin Yong Hong, Jungsu S Oh, Injoo Lee, Mun Kyung Sunwoo, Jee Hyun Ham, Ji E Lee, Young H Sohn, Jae Seung Kim, Phil Hyu Le. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. vol 82. issue 18. 2014-06-17. PMID:24719485. |
presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo parkinson disease. |
2014-06-17 |
2023-08-13 |
Not clear |
| Jin Yong Hong, Jungsu S Oh, Injoo Lee, Mun Kyung Sunwoo, Jee Hyun Ham, Ji E Lee, Young H Sohn, Jae Seung Kim, Phil Hyu Le. Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease. Neurology. vol 82. issue 18. 2014-06-17. PMID:24719485. |
to investigate whether the magnitude of presynaptic dopamine depletion is a risk factor for the development of levodopa-induced dyskinesia (lid) in parkinson disease (pd) by quantitatively analyzing (18)f-fp-cit pet data. |
2014-06-17 |
2023-08-13 |
Not clear |
| Elisabetta Tronci, Carlo Lisci, Roberto Stancampiano, Camino Fidalgo, Maria Collu, Paola Devoto, Manolo Cart. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiology of disease. vol 60. 2014-06-15. PMID:24004632. |
the serotonin system has recently emerged as an important player in the appearance of l-dopa-induced dyskinesia (lid) in experimental models of parkinson's disease, as it provides an unregulated source of l-dopa-derived dopamine release in the dopamine-depleted striatum. |
2014-06-15 |
2023-08-12 |
rat |
| N Jones, C Bleickardt, D Mullins, E Parker, R Hodgso. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain research bulletin. vol 98. 2014-05-30. PMID:23838432. |
because a2a receptor antagonists do not act on dopamine receptors, it has been hypothesized that they will not induce dyskinesias characteristic of l-dopa. |
2014-05-30 |
2023-08-12 |
rat |
| Nicola Simola, Micaela Morelli, Giuseppe Frazzitta, Lucia Fra. Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Frontiers in computational neuroscience. vol 7. 2014-04-22. PMID:24167489. |
abnormal involuntary movements (aims) and dyskinesias elicited by drugs that stimulate dopamine receptors in the basal ganglia are a major issue in the management of parkinson's disease (pd). |
2014-04-22 |
2023-08-12 |
rat |
| Milica Cerovic, Raffaele d'Isa, Raffaella Tonini, Riccardo Brambill. Molecular and cellular mechanisms of dopamine-mediated behavioral plasticity in the striatum. Neurobiology of learning and memory. vol 105. 2014-04-11. PMID:23827407. |
in addition, striatal activity is significantly altered in pathological conditions in which either a loss of dopamine innervation (parkinson's disease) or aberrant dopamine-mediated signaling (drug addiction and l-dopa induced dyskinesia) occurs. |
2014-04-11 |
2023-08-12 |
Not clear |
| Lisa Won, Yunmin Ding, Pardeep Singh, Un Jung Kan. Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 34. issue 8. 2014-04-10. PMID:24553948. |
3,4-dihydroxyphenyl-l-alanine (l-dopa)-induced dyskinesia (lid) is a debilitating side effect of long-term dopamine replacement therapy in parkinson's disease. |
2014-04-10 |
2023-08-12 |
mouse |
| Maria Papathanou, Rika van der Laan, Peter Jenner, Sarah Rose, Andrew C McCrear. Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Movement disorders : official journal of the Movement Disorder Society. vol 28. issue 8. 2014-03-06. PMID:23125107. |
the short duration of effect of levodopa is linked to pulsatile stimulation of striatal dopamine receptors and dyskinesia induction. |
2014-03-06 |
2023-08-12 |
rat |
| L Brusa, A Orlacchio, A Stefani, S Galati, M Pierantozzi, C Iani, N B Mercur. Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease. Functional neurology. vol 28. issue 2. 2014-02-26. PMID:24125559. |
since levodopa-induced peak dyskinesias (lids) may reflect, in part, a disproportionate phasic release of dopamine from synaptic vesicles, we examined the ability of the vesicular depletor tetrabenazine (tbz) to reduce lids in 10 dyskinetic advanced parkinson's disease (pd) patients. |
2014-02-26 |
2023-08-12 |
Not clear |
| C Marin, M Bonastre, G Mengod, R Cortés, M C Rodríguez-Oroz, J A Obes. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease. Experimental neurology. vol 250. 2014-01-30. PMID:24140562. |
moreover, intrasubthalamic microinfusion of dopamine in the mfb-lesion plus stn-lesion group triggered orolingual (p<0.01), but not axial or limb, dyskinesias. |
2014-01-30 |
2023-08-12 |
rat |
| Maryka Quik, Carla Campos, Tanuja Bordia, Jon-Paul Strachan, Jenny Zhang, J Michael McIntosh, Sharon Letchworth, Kristen Jorda. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. vol 71. 2014-01-10. PMID:23583932. |
l-dopa-induced dyskinesias are a serious long-term side effect of dopamine replacement therapy for parkinson's disease for which there are few treatment options. |
2014-01-10 |
2023-08-12 |
mouse |
| Maryka Quik, Carla Campos, Tanuja Bordia, Jon-Paul Strachan, Jenny Zhang, J Michael McIntosh, Sharon Letchworth, Kristen Jorda. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. vol 71. 2014-01-10. PMID:23583932. |
since α4α5β2 nachrs are also predominantly on striatal dopamine terminals, these data suggest that drugs targeting α4β2 nachrs may reduce l-dopa-induced dyskinesias in late stage parkinson's disease. |
2014-01-10 |
2023-08-12 |
mouse |
| Brenton A Wright, Cheryl H Water. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. Expert review of neurotherapeutics. vol 13. issue 6. 2014-01-09. PMID:23739008. |
exposure of striatal dopamine receptors to wildly fluctuating transmitter levels is thought to contribute to the development of dyskinesias and motor fluctuations. |
2014-01-09 |
2023-08-12 |
Not clear |
| Nirmal Bhide, David Lindenbach, Margaret A Surrena, Adam A Goldenberg, Christopher Bishop, S Paul Berger, Melanie A Paquett. The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology. vol 227. issue 3. 2013-12-13. PMID:23389756. |
the effects of bmy-14802 against l-dopa- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. |
2013-12-13 |
2023-08-12 |
rat |